Condition: Blepharoptosis · Sponsor: Santen Pharmaceutical Co., Ltd.
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis. At present, there are no medicines for the treatment of acquired blepharoptosis in China. Therefore, to evaluate the efficacy and safety of 0.1% STN1013800 ophthalmic solution, Vehicle (Placebo) are designed. For the screening period, 3-7 days were set to confirm the subjects and judge their qualification. Dosage and administration were based on prior clinical trial results approved at 0.1% once daily for 42 days treatment.
This description comes directly from the study's public registry record.
Santen Pharmaceuticals Co., Ltd Clinical Operations · +81-6-4802-9341 · clinical@santen.co.jp
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| The Second Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Beijing Chaoyang Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong | Shantou, Guangdong, China | Recruiting |
| Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| The first affiliated hospital of Zhengzhou University | Zhengzhou, He'nan, China | Recruiting |
| The 2nd Affiliated Hospital of Harbin Medical University | Ha’erbin, Helongjiang, China | Recruiting |
| Wuhan Aier Eye Hospital | Wuhan, Hubei, China | Recruiting |
| Xiangyang Central Hospital | Xiangyang, Hubei, China | Recruiting |
| Nanjing First Hospital | Nanjing, Jiangsu, China | Recruiting |
| The second norman bethune hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| Dalian No.3 Peple's Hospital | Dali, Liaoning, China | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06683651